Scinai Immunotherapeutics Ltd Cash Flow Conversion Efficiency
Scinai Immunotherapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Scinai Immunotherapeutics Ltd (SCNI) has a cash flow conversion efficiency ratio of -0.213x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.50 Million) by net assets ($11.73 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Scinai Immunotherapeutics Ltd (2006–2025)
Cash flow conversion efficiency of Scinai Immunotherapeutics Ltd from 2006 to 2025. This chart illustrates how Scinai Immunotherapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Scinai Immunotherapeutics Ltd (SCNI) share price today for real-time trading data and today's change.
Scinai Immunotherapeutics Ltd Cash Flow Conversion Ratio Explained
Scinai Immunotherapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Scinai Immunotherapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scinai Immunotherapeutics Ltd ranked by their cash flow conversion efficiency. Also see SCNI company net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
GO.D.M Investments Ltd
TA:GODM
|
-0.255x |
|
Desarrolladora Homex S.A.B. de C.V
MX:HOMEX
|
-0.024x |
|
Sanco Industries Limited
NSE:SANCO
|
0.025x |
|
Dewhurst plc
LSE:DWHA
|
0.062x |
|
Arcadia Biosciences Inc
NASDAQ:RKDA
|
-0.208x |
|
Windar Photonics Plc
LSE:WPHO
|
-0.022x |
|
Rivalry Corp
V:RVLY
|
-0.004x |
|
Bezant Resources Plc
LSE:BZT
|
-0.071x |
Annual Cash Flow Conversion Efficiency for Scinai Immunotherapeutics Ltd (2006–2025)
The table below shows the annual cash flow conversion efficiency of Scinai Immunotherapeutics Ltd from 2006 to 2025. Review SCNI FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $8.10 Million | $-6.03 Million | -0.744x | -17.22% |
| 2024-12-31 | $9.98 Million | $-6.33 Million | -0.635x | -130.92% |
| 2023-12-31 | $-4.57 Million | $-9.38 Million | 2.053x | -50.25% |
| 2022-12-31 | $-1.76 Million | $-7.26 Million | 4.128x | +154.59% |
| 2021-12-31 | $982.00K | $-7.43 Million | -7.562x | -262.81% |
| 2020-12-31 | $-4.54 Million | $-21.09 Million | 4.645x | +292.11% |
| 2019-12-31 | $-18.84 Million | $-22.31 Million | 1.185x | -35.35% |
| 2018-12-31 | $-8.35 Million | $-15.29 Million | 1.832x | +1125.54% |
| 2017-12-31 | $16.17 Million | $-2.89 Million | -0.179x | +52.59% |
| 2016-12-31 | $6.65 Million | $-2.51 Million | -0.377x | -23.12% |
| 2015-12-31 | $8.61 Million | $-2.63 Million | -0.306x | +32.95% |
| 2014-12-31 | $4.26 Million | $-1.94 Million | -0.457x | -160.40% |
| 2013-12-31 | $6.92 Million | $-1.21 Million | -0.175x | +42.74% |
| 2012-12-31 | $5.95 Million | $-1.82 Million | -0.306x | +24.07% |
| 2011-12-31 | $6.71 Million | $-2.71 Million | -0.403x | -39.67% |
| 2010-12-31 | $7.94 Million | $-2.29 Million | -0.289x | -185.60% |
| 2009-12-31 | $8.44 Million | $-852.95K | -0.101x | -1862.97% |
| 2006-12-31 | $1.74 Million | $10.00K | 0.006x | -- |
About Scinai Immunotherapeutics Ltd
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111, a human monoclonal antibody for the treatment of pemphigus, Steven Johnson's s… Read more